Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Sponsor: Halozyme Therapeutics
Terminated
Sponsor decision
Other terminated trials from Halozyme Therapeutics
A PHASE1 clinical study on Cholangiocarcinoma Non-resectable and Cholangiocarcinoma, Extrahepatic, this trial is terminated or withdrawn. The trial is conducted by Halozyme Therapeutics and has accumulated 25 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
25 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE1
▶ Show 20 earlier versions
-
Mar 2020 — Jan 2021 [monthly]
Terminated PHASE1
-
Jan 2020 — Mar 2020 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Nov 2019 — Jan 2020 [monthly]
Recruiting PHASE1
-
Oct 2019 — Nov 2019 [monthly]
Recruiting PHASE1
-
Sep 2019 — Oct 2019 [monthly]
Recruiting PHASE1
-
Aug 2019 — Sep 2019 [monthly]
Recruiting PHASE1
Status: Active Not Recruiting → Recruiting
-
Jul 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE1
-
May 2019 — Jul 2019 [monthly]
Active Not Recruiting PHASE1
-
Apr 2019 — May 2019 [monthly]
Active Not Recruiting PHASE1
-
Mar 2019 — Apr 2019 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Feb 2019 — Mar 2019 [monthly]
Recruiting PHASE1
-
Jan 2019 — Feb 2019 [monthly]
Recruiting PHASE1
-
Nov 2018 — Jan 2019 [monthly]
Recruiting PHASE1
-
Oct 2018 — Nov 2018 [monthly]
Recruiting PHASE1
-
Sep 2018 — Oct 2018 [monthly]
Recruiting PHASE1
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE1
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE1
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE1
-
Jan 2018 — Jun 2018 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Sep 2017 — Jan 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Halozyme Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .